Renoprotective effects of dulaglutide in patients with T2DM and CKD
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Nephrology"
DOI: 10.1038/s41581-018-0055-x
Abstract: The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients… read more here.
Keywords: effects dulaglutide; renoprotective effects; t2dm ckd; patients t2dm ... See more keywords
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.1111/dom.13028
Abstract: The aim was to determine the effects of dulaglutide, a synthetic once‐weekly, injectable human glucagon‐like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2… read more here.
Keywords: effects dulaglutide; trial; researching cardiovascular; baseline ... See more keywords